Stevanato Group announced today that liraglutide products incorporating its Alina pen injector received marketing authorization in Europe. Approved liraglutide-based combination products include Alina 30, developed for these therapies for diabetes, as well as Alina 50 for weight management applications. Both variants come as part of the company’s broader Alina variable-dose pen injector platform. The platform […]
Pharmaceuticals
Resilience, Lilly invest $750M in pharma, KwikPen manufacturing
Resilience announced today that it expanded its strategic partnership with Eli Lilly (NYSE:LLY) to increase medicine production in the U.S. The Cincinnati-based CDMO and the pharmaceutical giant first struck a partnership in 2023. Now, with $750 million invested, the companies are expanding Resilience’s advanced pharmaceutical manufacturing operations in Ohio. Now, Resilience’s production in that region […]
Micron Biomedical picks up $4.5M government contract for drug delivery patch
Micron Biomedical announced today that it received a $4.5 million contract from the National Institute of Allergy and Infectious Diseases (NIAID). NIAID (part of the NIH) awarded the contract to Micron to develop a dissolvable microarray medical countermeasure against radiation injury. The contract aims to enable rapid deployment of treatment for Acute Radiation Syndrome (ARS). […]
MannKind closes $50M financing, wins FDA nod for Furoscix auto-injector
MannKind (Nasdaq:MNKD) announced today that it secured $50 million in a private placement and earned a new regulatory nod. In addition to the funding, the company — which also develops inhaled insulin technology — won FDA approval for the Furoscix ReadyFlow auto-injector. MannKind said it entered into a securities purchase agreement in connection with a […]
Otsuka ICU Medical to invest $500M in IV solutions manufacturing in the US
Otsuka ICU Medical today announced plans to invest more than $500 million to expand its U.S. IV solutions manufacturing in Texas. The companies (Otsuka Pharmaceutical Factory and ICU Medical), which launched this joint venture last year, plan to deliver a new facility and significant upgrades to its existing operations in Austin, Texas. They expect the […]
BD names new president of Pharmacy Automation biz
BD (NYSE:BDX) announced today that it appointed Matthew Sassone as worldwide president of its Pharmacy Automation business. Sassone now leads the global business within the BD Medication Management Solutions business unit. His appointment goes into effect immediately. In the role, Sassone’s responsibilities include driving global strategy, performance and growth for Pharmacy Automation as part of […]
Terrestrial Bio doses first patients in GLP-1 patch trial
Terrestrial Bio announced today that it dosed the first patients in a Phase I clinical trial evaluating its patch that delivers GLP-1 therapeutic semaglutide. Boston-based Terrestrial (formerly Vaxess Technologies) is evaluating VX-201, a needle-free microarray patch (MAP) in the trial. The company designed its MAP technology features a soluble microarray with tips that gradually dissolve into […]
Anodyne picks up $12.6M to advance once-weekly GLP-1 patch
Anodyne Nanotech announced today that it closed a $12.6 million Series A financing to support its transdermal drug delivery technology. Velocity Partners VC led the round with co-leaders Evercurious VC, alongside major participation from Relativity Healthcare Partners. Boston-based Anodyne plans to use proceeds to support the advancement of ANN-101, its once-weekly GLP-1 patch for obesity. […]
Embecta names new SVP and president, North America
Embecta (Nasdaq:EMBC) announced that it appointed Nimish Muzumdar as its new SVP and president, North America. Muzumdar holds responsibility for leading the company’s U.S. and Canada commercial teams, executing the region’s long-term growth strategy. He reports to Chair, President and CEO, Dev Kurdikar, and serves on the Embecta operating team. His appointment went into effect […]
Terrestrial Bio data backs needle-free patch for GLP-1 delivery
Terrestrial Bio today shared new preclinical data demonstrating the translatability of its patch technology for delivering GLP-1 therapies. Boston-based Terrestrial (formerly Vaxess Technologies) shared findings at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. Outcomes showed the translatability of the proprietary Tacterra MAP platform to deliver next-generation obesity therapies that involve co-delivery […]
